Humuline 30/70 Patroon (Insulin Human (Rdna))

Humuline 30/70 Patroon is indicated for the management of hyperglycemia in adults with diabetes.

• Type 1 diabetes mellitus when basal and mealtime insulin are required.
• Type 2 diabetes mellitus as an adjunct to diet, exercise, and oral agents when insulin therapy is needed.
• Situations where a single injection can provide both basal and prandial coverage.
• Patients transitioning from separate rapid‑acting and intermediate‑acting insulin preparations.

• Humuline 30/70 Patroon contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the tyrosine‑kinase signaling cascade, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose output. The mixed‑ratio formulation supplies rapid‑acting insulin for post‑prandial glucose and intermediate‑acting insulin for basal control.

Like all insulin products, Humuline 30/70 Patroon may be associated with adverse reactions, ranging from mild to severe.

Common

• Hypoglycemia (low blood glucose)
• Injection site redness, swelling or itching
• Lipodystrophy at the injection site
• Weight gain

Serious

• Severe hypoglycemia with loss of consciousness or seizures
• Allergic reactions such as urticaria, angio‑edema, or anaphylaxis
• Persistent hyperglycemia indicating possible insulin resistance
• Edema or heart failure exacerbation

Clinicians should consider several precautions when prescribing Humuline 30/70 Patroon to ensure safe and effective use.

• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose closely when initiating therapy or changing the dose.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Counsel pregnant or breastfeeding women that safety data are limited; use only if benefits outweigh risks.
• Review concomitant medications that can mask hypoglycemia symptoms.

Humuline 30/70 Patroon can interact with other medicines, affecting glucose levels or insulin action.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose sulfonylureas or meglitinides that increase hypoglycemia risk.
• Beta‑blockers that may blunt hypoglycemia warning signs.

Use with caution

• Oral antihyperglycemics (e.g., metformin, thiazolidinediones) – monitor glucose closely.
• Corticosteroids, thyroid hormones, or growth hormone – may raise glucose requirements.
• Diuretics, especially thiazides – can affect electrolyte balance and glucose control.
• Alcohol – may cause delayed hypoglycemia.